Lenalidomide 5mg Capsule

Lenalidomide 5mg Capsule contains 5mg lenalidomide, an oral immunomodulatory anticancer medicine used in approved hematology-oncology treatment protocols. Generic lenalidomide 5mg is marketed as an alternative to Revlimid® 5mg, with manufacturer and packaging varying by product. Local terminology includes Lenalidomid 5 mg, lénalidomide 5 mg, 레날리도마이드 5mg and леналидомид 5 мг. Current U.S. labeling documents 5mg capsules, while Australia, France, Germany, South Korea and Russia also document 5mg lenalidomide capsule products.

Product Information

Generic Name

Lenalidomide

Strength

5mg

Dosage Form

Hard Capsule

Route

Oral

Drug Class

Immunomodulatory Antineoplastic Agent

Reference Brand

Revlimid® 5mg

Therapeutic Area

Hematologic Oncology

Prescription Status

Prescription medicine

Manufacturer

Varies by product

Pack Size

Varies by country and manufacturer

Generic Revlimid® 5mg

Revlimid® is the reference medicine containing lenalidomide. Generic lenalidomide 5mg contains the same active ingredient but may differ in manufacturer, capsule markings, inactive ingredients and packaging.

France's public medicines database currently identifies Lenalidomide Mylan 5mg as a generic and places it in the generic group corresponding to Revlimid 5mg.

Commercial Availability

High-intent searches around this strength include lenalidomide 5mg price, lenalidomide 5mg capsule, generic Revlimid 5mg, Revlimid 5mg capsule, lenalidomide 5mg cost, lenalidomide 5mg pharmacy and lenalidomide 5mg prescription.

Australia's current PBS listing includes lenalidomide 5mg capsules in 21- and 28-capsule presentations, with Lenalide, Lenalidomide Dr.Reddy's, Lenalidomide Sandoz and Revlimid listed as available brands.

Lenalidomide is used in approved treatment regimens for multiple myeloma and selected hematologic conditions, including certain myelodysplastic syndromes and lymphoma indications depending on the local authorization. The 5mg strength may be used as part of an individualized regimen, including situations where dose adjustment is required.

Lenalidomide is a high-risk prescription oncology medicine. Important risks include embryo-fetal toxicity, reduced blood-cell counts and venous or arterial thromboembolic events. Restricted-distribution and pregnancy-prevention requirements apply in major markets. Patients should use lenalidomide only under appropriate oncology supervision.